Pasi A. Jänne, MD, PhD, discusses the advantages of bispecific ADCs that target both HER3 and EGFR; preliminary efficacy and safety data seen with BL-B01D1 in patients with non–small cell lung cancer; and the activity of this agent in patients with head and neck squamous cell carcinoma, small cell lung cancer, and nasopharynx cancer.
Pasi A. Jänne, MD, PhD, discusses key trials evaluating the efficacy of single-agent osimertinib in patients with metastatic EGFR-mutated non–small cell lung cancer.
patients cancer early is tricky stop patients don t go to the gp unless patients don t go to the gp unless they have symptoms. the problem unless they have symptoms. the problem is unless they have symptoms. the problem is about 60% of those patients problem is about 60% of those patients that with see through that pathway to end up having a late stage cancer and any other cancers late stage cancer and any other cancers that we find him to be incidental. incidental. that is what this scheme is incidental. that is what this scheme is about. incidental. that is what this scheme is about. this - incidental. that is what thisj scheme is about. this week incidental. that is what this - scheme is about. this week the two or more hits six thousand scans. in that time, liz 45 lung cancers have been identified. smokers attending a lung track are getting help to quit as well. it lung track are getting help to quit as well- quit as well. it is never too late to stop quit as well.
never been known before. this part of new mexico, people were living a long time. they were living into the 90s, they were living over 100 years, and all of a sudden everybody s diming dying of leukemia, lung cancers, throw cancers, things that are tied directly to fall out. and imagine then learning that other down wonders were compensated but you weren t? you are going to feel both abandoned and that your voice is not heard. that is the worst kind of injustice. this is an explosive injustice right? so having the movie come out, kind of reminds them of all of it and reminds them the down winners of new mexico, but they are still forgotten unless we get this bill passed. i also want to point out, it is a bipartisan bill. it is been a bipartisan bill every year that we ve introduced it because there are down wonders in other states that were also left it.
Pasi A. Jänne, MD, PhD, details common EGFR mutations in NSCLC, the importance of testing for EGFR mutations in all patients, the clinical implications of overall survival data for adjuvant osimertinib from the ADAURA trial, and ongoing trials examining combination therapies to potentially improve upon the use of single-agent osimertinib.